Athenex, Inc. 的 Oraxol 獲得美國食品藥品管理局頒發就治療血管肉瘤的孤兒藥資格認定
April 20, 2018 08:09 ET | Athenex, Inc.
紐約州水牛城, April 20, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX) 是一家全球性的生物製藥公司,致力於發現、開發和商品化新型療法以治療癌症和相關病症。Athenex 今日宣布其治療血管肉瘤的 Oraxol 獲得美國食品藥品管理局 (FDA) 頒發就治療血管肉瘤的孤兒藥資格認定。Oraxol...
Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
April 19, 2018 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex將於第17屆年度Needham醫療健康會議上發表演講
March 27, 2018 11:04 ET | Athenex, Inc.
紐約州水牛城, March 27, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.(納斯達克:ATNX)是一家致力於發現、開發以及將癌症及相關疾病新型療法商業化的全球生物製藥公司。該公司今天宣佈,首席業務及與策略官Simon...
Athenex to Present at the 17th Annual Needham Healthcare Conference
March 27, 2018 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., March 27, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex, Inc. 公佈2017年第四季度及全年業績
March 26, 2018 20:53 ET | Athenex, Inc.
2017年第四季度及近期業務重點: Oraxol關於治療轉移性乳腺癌的第三期臨床試驗達到受試者的招募目標,並獲得美國FDA的正面反饋在KX2-391軟膏治療光化性角化病方面,宣佈與Almirall建立戰略合作關係Oraxol獲得英國藥物及保健產品規管局(MHRA)授予潛力創新藥(Promising Innovative...
Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results
March 26, 2018 07:00 ET | Athenex, Inc.
Fourth Quarter 2017 and Recent Business Highlights: Met enrollment targets and received positive feedback from the US FDA for Oraxol Phase III Clinical Trial in metastatic breast cancerAnnounced...
Athenex, Inc.將於2018年3月26日公布2017年第四季度和全年盈利業績
February 27, 2018 06:03 ET | Athenex, Inc.
紐約州水牛城, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc.(納斯達克﹕ATNX)是一家致力於發現、開發以及將治療癌症及相關疾病新型療法商業化的全球生物製藥公司。該公司將於2018年3月26日公布2017年第四季度和全年的盈利業績,並將於2018年3月26日(星期一)美國東岸時間上午9時正舉行電話會議和語音網上廣播。 ...
Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018
February 26, 2018 08:00 ET | Athenex, Inc.
BUFFALO, N.Y., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for...
Athenex在美國皮膚病學會會議上公佈KX2-391軟膏用於治療光化性角化病的第二期臨床研究結果
February 20, 2018 10:53 ET | Athenex, Inc.
紐約州水牛城, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX﹚是一家致力於發現、開發以及將癌症及相關疾病新療法商業化的全球生物製藥公司。該公司今天宣佈,2018年2月17日在加州聖地牙哥舉行的美國皮膚病學會年會上,坦帕市Forward Clinical Trials的Seth...
Athenex Announces Phase II Clinical Study Results for KX2-391 Ointment for the Treatment of Actinic Keratosis in the American Academy of Dermatology Meeting
February 20, 2018 08:11 ET | Athenex, Inc.
BUFFALO, N.Y., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the...